AQP9 upregulation in prostate cancer could enhance growth, migration, and invasion involving ERK1/2 signaling; reduced levels of phosphorylated ERK1/2 and MMP9 were observed in AQP9-deficient cell lines (Chen et al., 2016). Here, AQP9 is linked to prostate carcinoma.